# Second cancers caused by cancer drugs: monitoring on PARP inhibitors, BRAF inhibitors, lenalidomide, tamoxifen, radioligands and CAR T cells

Source: https://onco.cc/protocols/second-cancers-after-anticancer-drug-treatment/  
OnCo record `second-cancers-after-anticancer-drug-treatment` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some cancer medicines can lead to a new, different cancer during treatment or years later. Each medicine's label says what to watch for: regular blood counts on olaparib and niraparib, skin checks on vemurafenib, encorafenib and ripretinib, prompt tests for unexpected vaginal bleeding on tamoxifen, and lifelong follow-up after CAR T cells. Your own team's plan comes first.

## Summary

This page sets out what the US label and the EU summary of product characteristics (SmPC) ask for, product by product, with the few guideline statements that could be read. The local protocol and the label in force where the patient is treated come first.

PARP inhibitors. The US olaparib label reports myelodysplastic syndrome or acute myeloid leukaemia (MDS/AML) in approximately 1.2% (26/2219) of patients, and 8% against 4% with placebo in SOLO2. It asks for a blood count at baseline and monthly; for prolonged toxicity, interruption and weekly counts; referral to a haematologist, with bone marrow analysis and cytogenetics, if counts have not recovered to grade 1 or less after 4 weeks; and discontinuation if MDS/AML is confirmed. The EU SmPC recommends monthly counts for the first 12 months and periodically afterwards. For niraparib both labels ask for weekly counts in the first month; monthly counts then run for the next 11 months in the US label and the next 10 in the EU SmPC. The US label reports MDS/AML in 3.3% against 2.4% with placebo in PRIMA (HRD-positive patients) and 7% against 3% in the germline BRCA cohort of NOVA. ASCO's 2020 guideline, since replaced, recommended starting an evaluation for treatment-related MDS/AML when a cytopenia persists despite a drug hold; the living guideline that replaced it in October 2026 was read as an abstract only, which says clinicians should monitor for serious adverse events including MDS and AML.

Lutetium-177 dotatate. The US label reports MDS in 2.3% in NETTER-1, and in ERASMUS MDS in 2.0% and acute leukaemia in 0.5%, at a median of 29 and 55 months. The US label says to monitor blood cell counts and sets no schedule after treatment ends. The EU SmPC recommends blood counts, kidney and liver tests every 4 weeks for at least 3 months after the last infusion and every 6 months thereafter, to detect possible delayed adverse reactions. The NANETS/SNMMI procedure standard (2019) asks for blood tests at roughly 1, 3, 6 and 12 months after treatment, then at least yearly, and says a haematology consult should be considered for persistent cytopenias.

BRAF inhibitors and ripretinib. On vemurafenib, cutaneous squamous cell carcinoma or keratoacanthoma occurred in 24% (US label). Skin is examined before treatment and every 2 months in the US labels for vemurafenib, encorafenib and dabrafenib; the EU SmPCs ask for monthly examination on vemurafenib and dabrafenib and every 2 months on encorafenib. Suspicious lesions are excised and sent for dermatopathology and the drug continues at the same dose. The EU SmPCs add a head and neck examination and CT scans to look for cancers outside the skin (at set intervals for vemurafenib, as clinically appropriate for dabrafenib and encorafenib); the US labels ask for monitoring of signs and symptoms. Ripretinib (cutaneous squamous cell carcinoma in 4.7% of 85 patients in INVICTUS, US label): skin examination at the start and routinely, in both labels.

Lenalidomide. After high-dose melphalan and autologous transplant, haematological second cancers occurred in 7.5% on maintenance against 3.3% on placebo (US label). The US label says to monitor for second primary malignancies and to weigh the benefit of lenalidomide against that risk; the EU SmPC asks for standard cancer screening before and during treatment.

Tamoxifen. Abnormal vaginal bleeding during or after tamoxifen is evaluated promptly (US label, UK SmPC); ACOG says any abnormal vaginal bleeding in a woman taking tamoxifen should be investigated. The US label also asks for an annual gynaecological examination; the UK SmPC read does not. ACOG does not recommend routine endometrial surveillance unless the woman is at high risk of endometrial cancer.

CAR T cells. The US labels of all six BCMA- and CD19-directed products (ciltacabtagene autoleucel, idecabtagene vicleucel, lisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel and axicabtagene ciloleucel), the EU SmPC for ciltacabtagene autoleucel, the FDA and the EMA's safety committee all ask for lifelong monitoring for secondary malignancies. The labels and the FDA also ask for the manufacturer to be contacted if one occurs, to get instructions on samples for testing.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: second primary malignancy monitoring; therapy-related MDS and AML; secondary malignancies after CAR T; new primary cutaneous malignancies; skin checks on BRAF inhibitors; tamoxifen and womb cancer; MDS/AML on PARP inhibitors; SPM on lenalidomide

## Connected records

- protocols: [Blood count, kidney and liver monitoring during lutetium-177 radioligand therapy](https://onco.cc/protocols/blood-count-and-kidney-monitoring-during-radioligand-therapy/), [Bone marrow aspirate and trephine biopsy: preparation, pain control and aftercare](https://onco.cc/protocols/bone-marrow-aspirate-and-trephine-biopsy/), [Breast screening after chest radiotherapy at a young age](https://onco.cc/protocols/breast-screening-after-chest-radiotherapy-at-a-young-age/), [End of treatment: treatment summary, survivorship care plan and handover to primary care](https://onco.cc/protocols/survivorship-care-plan-and-treatment-summary/), [Follow-up after treatment for early breast cancer](https://onco.cc/protocols/breast-cancer-follow-up-after-treatment/), [Long-term follow-up after childhood, teenage and young adult cancer, planned by the treatment received](https://onco.cc/protocols/long-term-follow-up-after-childhood-cancer/), [Sun protection during and after cancer treatment](https://onco.cc/protocols/sun-protection-during-and-after-cancer-treatment/)
- cancers: [Secondary and therapy-related acute myeloid leukaemia](https://onco.cc/cancers/aml-secondary/)
- technologies: [Skin cancer screening (visual skin examination)](https://onco.cc/technologies/skin-cancer-screening/)
- drugs: [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Brexucabtagene autoleucel](https://onco.cc/drugs/brexucabtagene-autoleucel/), [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/), [Dabrafenib](https://onco.cc/drugs/dabrafenib/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [Idecabtagene vicleucel](https://onco.cc/drugs/idecabtagene-vicleucel/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Lisocabtagene maraleucel](https://onco.cc/drugs/lisocabtagene-maraleucel/), [Lutetium-177 dotatate](https://onco.cc/drugs/lutathera/), [Niraparib](https://onco.cc/drugs/niraparib/), [Olaparib](https://onco.cc/drugs/olaparib/), [Ripretinib](https://onco.cc/drugs/ripretinib/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/), [Tisagenlecleucel](https://onco.cc/drugs/tisagenlecleucel/), [Vemurafenib](https://onco.cc/drugs/vemurafenib/)
- terms: [Bone marrow](https://onco.cc/terms/bone-marrow/), [Cytogenetics and karyotype](https://onco.cc/terms/cytogenetics/), [Keratoacanthoma: the tumour that may be a squamous cell carcinoma](https://onco.cc/terms/keratoacanthoma/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Squamous cell carcinoma](https://onco.cc/terms/squamous-cell-carcinoma/)

---
JSON: https://onco.cc/api/v1/entities/second-cancers-after-anticancer-drug-treatment.json